Pharmacogenetic Tests for Antipsychotic Medications: Clinical Implications and Considerations

Overview

Journal Dialogues Clin Neurosci

Specialty Neurology

Date 2016 Oct 21

PMID 27757066

Citations 20

Authors

Seenae Eum

Adam M Lee

Jeffrey R Bishop

Affiliations

Soon will be listed here.

Abstract

Optimizing antipsychotic pharmacotherapy is often challenging due to significant variability in effectiveness and tolerability. Genetic factors influencing pharmacokinetics and pharmacodynamics may contribute to some of this variability. Research studies have characterized these pharmacogenetic relationships, and some genetic markers are now available as clinical tests. These advances in pharmacogenetics research and test availability have great potential to improve clinical outcomes and quality of life in psychiatric patients. For clinicians considering using pharmacogenetics, it is important to understand the clinical implications and also the limitations of markers included in currently available tests. This review focuses on pharmacokinetic and pharmacodynamic gene variants that are currently available in commercial genetic testing panels. Associations of these variants with clinical efficacy and adverse effects, as well as other clinical implications, in antipsychotic pharmacotherapy are discussed.

Citing Articles

Cognitive Impairments Related to COMT and Neuregulin 1 Phenotypes as Transdiagnostic Markers in Schizophrenia Spectrum Patients.

Bondrescu M, Dehelean L, Farcas S, Papava I, Nicoras V, Podaru C J Clin Med. 2024; 13(21).

PMID: 39518545 PMC: 11546985. DOI: 10.3390/jcm13216405.

Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia.

Sanguesa E, Fernandez-Egea E, Concha J, Garcia C, Ribate M Biomedicines. 2024; 12(3).

PMID: 38540209 PMC: 10967865. DOI: 10.3390/biomedicines12030597.

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.

Jameson A, Faisal M, Fylan B, Bristow G, Sohal J, Dalton C J Psychopharmacol. 2024; 38(4):382-394.

PMID: 38494658 PMC: 11010551. DOI: 10.1177/02698811241238283.

Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism.

Shilbayeh S, Adeen I, Ghanem E, Aljurayb H, Aldilaijan K, AlDosari F Front Pharmacol. 2024; 15:1356763.

PMID: 38375040 PMC: 10875102. DOI: 10.3389/fphar.2024.1356763.

Relationship of Single Nucleotide Polymorphism to the Efficiency and Safety Profiles of Haloperidol in Patients Enduring Acute Alcoholic Hallucinosis.

Parkhomenko A, Zastrozhin M, Skryabin V, Petukhov A, Pozdniakov S, Ivanchenko V Psychopharmacol Bull. 2023; 53(4):8-14.

PMID: 38076668 PMC: 10698852.

References

Wallace T, Zai C, Brandl E, Muller D . Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmgenomics Pers Med. 2012; 4:83-93. PMC: 3513221. DOI: 10.2147/PGPM.S11866. View

Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M . Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996; 278(1):441-6. View

Pan Y, Qiao L, Xue X, Fu J . Association between ANKK1 (rs1800497) polymorphism of DRD2 gene and attention deficit hyperactivity disorder: a meta-analysis. Neurosci Lett. 2015; 590:101-5. DOI: 10.1016/j.neulet.2015.01.076. View

van der Weide J, Steijns L, van Weelden M . The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003; 13(3):169-72. DOI: 10.1097/00008571-200303000-00006. View

Arranz M, Collier D, Munro J, Sham P, Kirov G, Sodhi M . Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 1996; 217(2-3):177-8. View

Muller D, Zai C, Sicard M, Remington E, Souza R, Tiwari A . Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2010; 12(2):156-64. DOI: 10.1038/tpj.2010.65. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E . The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006; 5(1):25-43. DOI: 10.2174/187152706784111551. View

Lerer B, Segman R, Tan E, Basile V, Cavallaro R, Aschauer H . Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol. 2005; 8(3):411-25. DOI: 10.1017/S1461145705005389. View

10.

Cacabelos R, Hashimoto R, Takeda M . Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci. 2011; 65(1):3-19. DOI: 10.1111/j.1440-1819.2010.02168.x. View

11.

Parsons M, DSouza U, Arranz M, Kerwin R, Makoff A . The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry. 2004; 56(6):406-10. DOI: 10.1016/j.biopsych.2004.06.020. View

12.

Bertolino A, Caforio G, Blasi G, Rampino A, Nardini M, Weinberger D . COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res. 2007; 95(1-3):253-5. DOI: 10.1016/j.schres.2007.06.014. View

13.

Soderberg M, Molden E, Dahl M . No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients. Pharmacogenet Genomics. 2014; 24(5):272-5. DOI: 10.1097/FPC.0000000000000041. View

14.

Kimchi-Sarfaty C, Oh J, Kim I, Sauna Z, Calcagno A, Ambudkar S . A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2006; 315(5811):525-8. DOI: 10.1126/science.1135308. View

15.

Calarge C, Ellingrod V, Acion L, Miller D, Moline J, Tansey M . Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009; 19(5):373-82. PMC: 2699901. DOI: 10.1097/FPC.0b013e328329a60f. View

16.

Hagg S, Spigset O, Lakso H, Dahlqvist R . Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol. 2001; 57(6-7):493-7. DOI: 10.1007/s002280100343. View

17.

Rasmussen B, Brix T, Kyvik K, Brosen K . The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002; 12(6):473-8. DOI: 10.1097/00008571-200208000-00008. View

18.

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

19.

Joyce J, Gurevich E . D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann N Y Acad Sci. 1999; 877:595-613. DOI: 10.1111/j.1749-6632.1999.tb09291.x. View

20.

Zanger U, Turpeinen M, Klein K, Schwab M . Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008; 392(6):1093-108. DOI: 10.1007/s00216-008-2291-6. View